https://mavengity.com/articles/finance/sec-meyer-global-spacex-pre-ipo-funds/ Mavengity en 2026-09-30T23:42:25+02:00 SEC says a pre-IPO fund adviser promised SpaceX share distributions after the shares were gone https://mavengity.com/articles/finance/trump-accounts-auto-enrollment-temporary-regulations/ Mavengity en 2026-09-30T16:43:13+02:00 Treasury starts opening Trump accounts for eligible children on October 1 https://mavengity.com/articles/legal/oakland-police-monitorship-ends-23-years/ Mavengity en 2026-09-30T14:51:58+02:00 The Longest-Running Police Monitorship in U.S. History Ends in Oakland https://mavengity.com/articles/healthcare-medical/counterfeit-ozempic-supply-chain-indictment/ Mavengity en 2026-09-30T14:51:55+02:00 Counterfeit Ozempic Kept Moving After the FDA's Warning https://mavengity.com/articles/legal/dc-circuit-boasberg-contempt-probe-deportation-flights/ Mavengity en 2026-09-30T14:51:53+02:00 The Full D.C. Circuit Weighs Whether a Judge Can Investigate the Executive https://mavengity.com/articles/legal/white-house-ai-accord-self-policing/ Mavengity en 2026-09-30T14:51:51+02:00 Six AI Companies Agree to Police Themselves Under a White House Accord https://mavengity.com/articles/healthcare-medical/immix-nxc-201-nexicart-2-89-percent-cr/ Mavengity en 2026-09-30T13:49:01+02:00 Immix Priced a $125 Million Offering on an 89 Percent Response Rate https://mavengity.com/articles/healthcare-medical/dyne-z-basivarsen-achieve-one-year-dm1/ Mavengity en 2026-09-30T13:48:50+02:00 Dyne's One-Year DM1 Data Land on the Endpoint Novartis Just Missed https://mavengity.com/articles/healthcare-medical/invivyd-vyd2311-liberty-titers-approval-path/ Mavengity en 2026-09-30T13:48:10+02:00 Invivyd Wants Its COVID Antibody Approved on Titers, Not Outcomes https://mavengity.com/articles/legal/sec-crypto-ai-trading-platform-confidence-scams/ Mavengity en 2026-09-30T00:40:19+02:00 Two Trading Platforms Turned the SEC's Own Filing System Into a Sales Pitch https://mavengity.com/articles/healthcare-medical/emcitate-tiratricol-mct8-deficiency-first-approval/ Mavengity en 2026-09-30T00:33:51+02:00 MCT8 Deficiency's First Approved Drug Carries a Warning Against the Use It Was Sold For https://mavengity.com/articles/legal/openai-withholds-gpt-6-1-astra-alignment-bar/ Mavengity en 2026-09-29T18:29:11+02:00 OpenAI Held Back GPT-6.1 Astra, and the Only Bar It Failed Is Its Own https://mavengity.com/articles/finance/farmland-installment-election-ten-year-covenant/ Mavengity en 2026-09-29T16:32:04+02:00 Farmland Sold to a Working Farmer Spreads the Tax Over Four Years, at the Price of a Ten-Year Covenant https://mavengity.com/articles/finance/anthropic-ipo-518-billion-compute-commitments/ Mavengity en 2026-09-29T15:29:40+02:00 Anthropic's IPO Prospectus Commits $518 Billion, Most of It Payable Regardless of Use https://mavengity.com/articles/healthcare-medical/kodiak-daybreak-zenkuda-six-month-dosing-comparator/ Mavengity en 2026-09-29T13:29:40+02:00 Kodiak's Twice-Failed Retina Drug Reached Six-Month Dosing in a Majority of Patients https://mavengity.com/articles/legal/ftc-personalized-pricing-disclosure-scope/ Mavengity en 2026-09-29T12:48:59+02:00 The FTC's Answer to Personalized Pricing Is a Label at Checkout https://mavengity.com/articles/finance/zoe-financial-adviser-referral-algorithm-settlement/ Mavengity en 2026-09-28T23:46:39+02:00 The SEC Fined Zoe Financial Over Who Really Picked Its Clients' Advisers